文献速递腹部妇产影像PET

FAPI PET/CT检测腹膜转移诊断效能的系统综述与荟萃分析

Diagnostic performance of FAPI PET/CT for the detection of peritoneal metastases: an updated systematic review and bivariate meta-analysis.
PubMed 文献 · Eur J Radiol · 2026-06-16

以组织病理和/或多学科综合判断为参考标准,患者水平诊断敏感度为97%、特异度为95%、AUC为0.99;病灶水平敏感度为92%、特异度为90%、AUC为0.96。结论认为FAPI PET/CT在检测腹膜转移方面具有良好且有临床价值的诊断效能,但尚需前瞻性验证。

要点

  • FAPI PET/CT患者水平检测腹膜转移敏感度97%、特异度95%,可用于评估有无腹膜受累。
  • 病灶水平敏感度92%、特异度90%,解析腹膜受累范围表现可靠。
  • 卵巢癌来源病灶水平汇总敏感度92%、特异度96%,在腹膜转移高发瘤种中价值突出。

核心结论

  • FAPI PET/CT在患者水平和病灶水平分析中均显示出有临床价值的腹膜转移检测效能。
  • 该技术支持评估腹膜受累的存在及范围,尤其在卵巢癌等易发生腹膜转移的瘤种中具有价值。
  • 仍需前瞻性验证研究进一步确认其临床地位。

研究设计与样本

  • 研究类型为基于诊断准确性研究的更新系统综述与双变量随机效应荟萃分析。
  • 检索范围包括PubMed和Embase数据库,截止时间为2026年1月。
  • 参考标准为组织病理学和/或多学科综合判断。
  • 使用双变量随机效应模型汇总敏感度、特异度及综合受试者工作特征曲线下面积(AUC)。

诊断标准与关键数值

  • 以患者水平分析,FAPI PET/CT检测腹膜转移的汇总敏感度为97%(95%CI,91-99%),特异度为95%(95%CI,80-99%),AUC为0.99(95%CI,0.98-1.00)。
  • 以病灶水平分析,FAPI PET/CT检测腹膜转移的汇总敏感度为92%(95%CI,83-96%),特异度为90%(95%CI,70-97%),AUC为0.96(95%CI,0.94-0.97)。
  • 4项卵巢癌研究的病灶水平数据汇总敏感度为92%(95%CI,79-97%),汇总特异度为96%(95%CI,85-99%)。

临床应用与阅片要点

  • 患者水平极高的敏感度和AUC提示FAPI PET/CT所得阴性结果对排除腹膜转移具有临床价值。
  • 病灶水平分析可用于判断腹膜转移的扩散范围,帮助治疗方案制定。
  • 在卵巢癌等腹膜转移高发瘤种中可考虑将FAPI PET/CT纳入腹膜受累评估。

局限性

  • 原文指出仍需要前瞻性验证研究进一步确认诊断价值。
  • 患者水平特异度的95%CI范围较宽(80-99%),提示该估计值存在不确定性。
  • 病灶水平特异度的95%CI较宽(70-97%),提示假阳性率估计不稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To perform an updated systematic review and meta-analysis on the diagnostic accuracy of FAPI PET/CT in detecting peritoneal metastases (PM) in various cancer patients.

METHODS: The PubMed and Embase databases were searched through January 2026 to identify relevant articles. We included studies reporting the diagnostic accuracy of FAPI PET/CT in detecting PM in cancer patients, using histopathology and/or a multidisciplinary approach as the reference standard. The pooled sensitivity, specificity, and area under the summary receiver-operating characteristics curve (AUC) were determined by using a bivariate random-effects model.

RESULTS: Fifteen studies with 837 patients were eligible, of which nine provided patient-level data, five provided lesion-level data, and one provided both types of data. On patient-based analysis, the pooled sensitivity, specificity, and AUC value for FAPI PET/CT in detecting PM were 97 % (95 % CI, 91-99 %), 95 % (95 % CI, 80-99 %), and 0.99 (95 % CI, 0.98-1.00), respectively. On lesion-based analysis, the pooled sensitivity, specificity, and AUC value for FAPI PET/CT in detecting PM were 92 % (95 % CI, 83-96 %), 90 % (95 % CI, 70-97 %), and 0.96 (95 % CI, 0.94-0.97), respectively. Of note, lesion-based data from four ovarian cancer studies showed a pooled sensitivity of 92 % (95 % CI, 79-97 %) and a pooled specificity of 96 % (95 % CI, 85-99 %).

CONCLUSION: This updated meta-analysis showed that FAPI PET/CT has promising and clinically relevant diagnostic performance for the detection of PM in both patient-based and lesion-based analyses. These findings support its value for evaluating the presence and extent of peritoneal involvement, particularly in PM-prone cancers such as ovarian cancer, while further prospective validation is still warranted.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Qi-Chang, Kai-Yin, Cheng-Yi, et al. Diagnostic performance of FAPI PET/CT for the detection of peritoneal metastases: an updated systematic review and bivariate meta-analysis. Eur J Radiol. 2026. PMID: 42320141. doi:10.1016/j.ejrad.2026.113011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。